{"id":"raltegravir-ral","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":{"chemblId":"CHEMBL254316","moleculeType":"Small molecule","molecularWeight":"444.42"},"_dailymed":{"setId":"89a5ec53-d956-4329-8004-0f40f51c88a3","title":"ISENTRESS (RALTEGRAVIR) TABLET, FILM COATED ISENTRESS (RALTEGRAVIR) TABLET, CHEWABLE ISENTRESS (RALTEGRAVIR) GRANULE, FOR SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raltegravir is an integrase strand transfer inhibitor (INSTI) that binds to HIV integrase and blocks the catalytic activity required for viral DNA integration into the human genome. By preventing integration, the drug stops HIV replication at a critical step in the viral lifecycle. This mechanism is distinct from reverse transcriptase and protease inhibitors, offering an alternative pathway for antiretroviral therapy.","oneSentence":"Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:10.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve adults and children"},{"name":"HIV-1 infection in treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT04258475","phase":"PHASE4","title":"The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-12-09","conditions":"Calcium Supplementation in HIV Patients Using Raltegravir","enrollment":12},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT01231516","phase":"PHASE3","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-26","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":724},{"nctId":"NCT01828073","phase":"","title":"Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05-19","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01780831","phase":"PHASE1","title":"Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-28","conditions":"HIV Infections","enrollment":52},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01159132","phase":"PHASE2","title":"Pharmacokinetics of Low Dose Raltegravir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT00718536","phase":"PHASE4","title":"Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-08","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00685191","phase":"PHASE4","title":"HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-06","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01258374","phase":"","title":"Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-05","conditions":"Integrase Inhibitors, HIV; HIV PROTEASE INHIB","enrollment":15},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT03842488","phase":"PHASE4","title":"Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT03732625","phase":"PHASE4","title":"Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2019-05","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02273765","phase":"PHASE3","title":"Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-09-11","conditions":"HIV-1 Infection, Tuberculosis","enrollment":460},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00830804","phase":"PHASE2","title":"Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-04","conditions":"HIV-1 Infections","enrollment":113},{"nctId":"NCT01078246","phase":"","title":"Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-31","conditions":"HIV-1 Infections","enrollment":7124},{"nctId":"NCT02765776","phase":"","title":"An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens in Aged HIV Patients (RalAge)","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2016-05","conditions":"HIV","enrollment":90},{"nctId":"NCT01450189","phase":"NA","title":"A Key Link for Transmission Prevention","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-10","conditions":"HIV","enrollment":46},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT00641641","phase":"NA","title":"The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2008-03","conditions":"HIV Infection","enrollment":16},{"nctId":"NCT01214486","phase":"NA","title":"Measurement of Plasma and Intracellular Concentrations of Raltegravir","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2010-10-01","conditions":"HIV","enrollment":12},{"nctId":"NCT01978743","phase":"NA","title":"Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity","enrollment":10},{"nctId":"NCT01900015","phase":"PHASE4","title":"Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection","status":"COMPLETED","sponsor":"Juan Macías","startDate":"2014-02-03","conditions":"HCV Coinfection, HIV Infection","enrollment":45},{"nctId":"NCT01456962","phase":"","title":"Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-10","conditions":"Women's Health, HIV Infection, Genital Diseases, Female","enrollment":36},{"nctId":"NCT03158077","phase":"","title":"Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2016-11-15","conditions":"HIV Infections","enrollment":467},{"nctId":"NCT01622673","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00814879","phase":"NA","title":"Pilot Study of a Raltegravir Based NRTI Sparing Regimen","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-05","conditions":"Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus","enrollment":60},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01291459","phase":"PHASE2","title":"Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients","status":"UNKNOWN","sponsor":"Association Pour la Recherche en Infectiologie","startDate":"2011-09","conditions":"HIV","enrollment":40},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01576731","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-07","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT00773708","phase":"PHASE4","title":"Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-03","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT01327482","phase":"NA","title":"Levels of Raltegravir in the Female Genital Tissue","status":"COMPLETED","sponsor":"University of Washington","startDate":"2011-10","conditions":"HIV","enrollment":10},{"nctId":"NCT00749580","phase":"NA","title":"A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2008-11","conditions":"Virus Diseases, HIV","enrollment":46},{"nctId":"NCT00700115","phase":"PHASE4","title":"Kaletra-isentress Treatment Evaluation","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-06","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT02219672","phase":"PHASE3","title":"Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2014-07","conditions":"AIDS/HIV PROBLEM","enrollment":18},{"nctId":"NCT01270802","phase":"PHASE4","title":"Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-04","conditions":"HIV","enrollment":30},{"nctId":"NCT01330199","phase":"PHASE1","title":"Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-02","conditions":"Healthy Adult Females","enrollment":49},{"nctId":"NCT01844310","phase":"NA","title":"Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2013-05","conditions":"AIDS/HIV PROBLEM","enrollment":300},{"nctId":"NCT01381328","phase":"","title":"GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance","status":"UNKNOWN","sponsor":"Università Vita-Salute San Raffaele","startDate":"2011-12","conditions":"HIV-1 Infected Patients, Fold-change Resistance, Resistance Mutations","enrollment":100},{"nctId":"NCT00858962","phase":"NA","title":"Buprenorphine/Raltegravir Pharmacokinetic Interaction Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":12},{"nctId":"NCT00711009","phase":"PHASE3","title":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infection","enrollment":206},{"nctId":"NCT00523237","phase":"NA","title":"RAL-eve Study: Raltegravir Substitution Study","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-10","conditions":"HIV Infections","enrollment":14},{"nctId":"NCT00488059","phase":"PHASE4","title":"A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT01201239","phase":"PHASE4","title":"Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2010-09","conditions":"HIV","enrollment":50},{"nctId":"NCT01066065","phase":"","title":"Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2010-02","conditions":"Cardiovascular Disease, HIV Infections","enrollment":120},{"nctId":"NCT00941083","phase":"PHASE4","title":"Simplification From Protease Inhibitors to Raltegravir","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2009-01","conditions":"HIV Infections","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["raltegravir","RAL","Isentress","MK-0518"],"phase":"marketed","status":"active","brandName":"raltegravir (RAL)","genericName":"raltegravir (RAL)","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir (RAL) is a small molecule used to treat conditions such as Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections, and HIV Infection. It is used in combination with other treatments, including Atazanavir and Standard treatment regimens, as part of a regimen that may spare the use of NRTIs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}